Ionizing Radiation Exposure and Basal Cell Carcinoma Pathogenesis

Radiation Research

Volumn 185, Issue 3, 2016, Pages 217-228

  Li, Changzhao ^a   Athar, Mohammad ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN PATCHED; VISMODEGIB; ANILIDE; PYRIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN;

ATOMIC BOMB SURVIVOR; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CAUCASIAN; CHERNOBYL ACCIDENT; CHILDHOOD CANCER; GRAFT RECIPIENT; HUMAN; IONIZING RADIATION; LONG TERM EXPOSURE; MEDICAL PERSONNEL; OCCUPATIONAL EXPOSURE; PATHOGENESIS; PRIORITY JOURNAL; RACE; RADIATION EXPOSURE; REVIEW; SIGNAL TRANSDUCTION; TINEA CAPITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ATOMIC BOMB; CARCINOMA, BASAL CELL; GENETICS; NEOPLASMS, RADIATION-INDUCED; PATHOLOGY; SKIN NEOPLASMS; SURVIVOR;

ANILIDES; ANIMALS; CARCINOMA, BASAL CELL; CHERNOBYL NUCLEAR ACCIDENT; HEDGEHOG PROTEINS; HUMANS; NEOPLASMS, RADIATION-INDUCED; NUCLEAR WEAPONS; PYRIDINES; RADIATION EXPOSURE; RADIATION, IONIZING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SURVIVORS;

EID: 84979732795     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR4284.S1     Document Type: Review

References (130)

1. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. A review of human carcinogens-part D: radiation. Lancet Oncol 2009; 10:751-2.
2. Athar M, Li C, Kim AL, Spiegelman VS, Bickers DR. Sonic hedgehog signaling in Basal cell nevus syndrome. Cancer Res 2014; 74:4967-75.
3. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8:743-54.
4. Lacour JP. Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms. Br J Dermatol 2002; 146 Suppl 61:17-9.
5. Mizuno T, Tokuoka S, Kishikawa M, Nakashima E, Mabuchi K, Iwamoto KS. Molecular basis of basal cell carcinogenesis in the atomic-bomb survivor population: p53 and PTCH gene alterations. Carcinogenesis 2006; 27:2286-94.
6. Kasper M, Jaks V, Hohl D, Toftgard R. Basal cell carcinoma-molecular biology and potential new therapies. J Clin Invest 2012; 122:455-63.
7. Unden AB, Holmberg E, Lundh-Rozell B, Stahle-Backdahl M, Zaphiropoulos PG, Toftgard R, et al. Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: different in vivo mechanisms of PTCH inactivation. Cancer Res 1996; 56:4562-5.
8. Pazzaglia S, Mancuso M, Tanori M, Atkinson MJ, Merola P, Rebessi S, et al. Modulation of patched-associated susceptibility to radiation induced tumorigenesis by genetic background. Cancer Res 2004; 64:3798-806.
9. Aszterbaum M, Epstein J, Oro A, Douglas V, LeBoit PE, Scott MP, et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med 1999; 5:1285-91.
10. Willey JC, Harris CC. Cellular and molecular biological aspects of human bronchogenic carcinogenesis. Crit Rev Oncol Hematol 1990; 10:181-209.
11. Wakeford R. Radiation in the workplace - a review of studies of the risks of occupational exposure to ionising radiation. J Radiol Prot 2009; 29(2A):A61-79.
12. Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24:1119-26.
13. Yoshinaga S, Hauptmann M, Sigurdson AJ, Doody MM, Freedman DM, Alexander BH, et al. Nonmelanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists. Int J Cancer 2005; 115:828-34.
14. Yoshinaga S, Mabuchi K, Sigurdson AJ, Doody MM, Ron E. Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies. Radiology 2004; 233:313-21.
15. Ron E, Modan B, Preston D, Alfandary E, Stovall M, Boice JD, Jr. Radiation-induced skin carcinomas of the head and neck. Radiat Res 1991; 125:318-25.
16. Shore RE, Albert RE, Reed M, Harley N, Pasternack BS. Skin cancer incidence among children irradiated for ringworm of the scalp. Radiat Res 1984; 100:192-204.
17. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat Res 1994; 137(2 Suppl): S17-67.
18. Sugiyama H, Misumi M, Kishikawa M, Iseki M, Yonehara S, Hayashi T, et al. Skin cancer incidence among atomic bomb survivors from 1958 to 1996. Radiat Res 2014; 181:531-9.
19. Williams D. Radiation carcinogenesis: lessons from Chernobyl. Oncogene 2008; 27 Suppl 2:S9-18.
20. Naruke Y, Nakashima M, Suzuki K, Kondo H, Hayashi T, Soda M, et al. Genomic instability in the epidermis induced by atomic bomb (A-bomb) radiation: a long-lasting health effect in A-bomb survivors. Cancer 2009; 115:3782-90.
21. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007; 168:1-64.
22. Kishikawa M, Koyama K, Iseki M, Kobuke T, Yonehara S, Soda M, et al. Histologic characteristics of skin cancer in Hiroshima and Nagasaki: background incidence and radiation effects. Int J Cancer 2005; 117:363-9.
23. Ron E, Preston DL, Kishikawa M, Kobuke T, Iseki M, Tokuoka S, et al. Skin tumor risk among atomic-bomb survivors in Japan. Cancer Causes Control 1998; 9:393-401.
24. Chaudhary SC, Tang X, Arumugam A, Li C, Srivastava RK, Weng Z, et al. Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndrome. Oncotarget 2015; 6:36789-814.
25. Gottlober P, Steinert M, Weiss M, Bebeshko V, Belyi D, Nadejina N, et al. The outcome of local radiation injuries: 14 years of follow-up after the Chernobyl accident. Radiat Res 2001; 155:409-16.
26. Bouville A, Likhtarev IA, Kovgan LN, Minenko VF, Shinkarev SM, Drozdovitch VV. Radiation dosimetry for highly contaminated Belarusian, Russian and Ukrainian populations, and for less contaminated populations in Europe. Health Phys 2007; 93:487-501.
27. Romanenko A, Morimura K, Wanibuchi H, Salim EI, Kinoshita A, Kaneko M, et al. Increased oxidative stress with gene alteration in urinary bladder urothelium after the Chernobyl accident. Int J Cancer 2000; 86:790-8.
28. Steinert M, Weiss M, Gottlober P, Belyi D, Gergel O, Bebeshko V, et al. Delayed effects of accidental cutaneous radiation exposure: fifteen years of follow-up after the Chernobyl accident. J Am Acad Dermatol 2003; 49:417-23.
29. Cardis E, Krewski D, Boniol M, Drozdovitch V, Darby SC, Gilbert ES, et al. Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. Int J Cancer 2006; 119:1224-35.
30. Prysyazhnyuk A, Gristchenko V, Fedorenko Z, Gulak L, Fuzik M, Slipenyuk K, et al. Twenty years after the Chernobyl accident: solid cancer incidence in various groups of the Ukrainian population. Radiat Environ Biophys 2007; 46:43-51.
31. Watt TC, Inskip PD, Stratton K, Smith SA, Kry SF, Sigurdson AJ, et al. Radiation-related risk of basal cell carcinoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2012; 104:1240-50.
32. DePry JL, Vyas R, Lazarus HM, Caimi PF, Gerstenblith MR, Bordeaux JS. Cutaneous malignant neoplasms in hematopoietic cell transplant recipients: A systematic review. JAMA Dermatol 2015; 151:775-82.
33. Schwartz JL, Kopecky KJ, Mathes RW, Leisenring WM, Friedman DL, Deeg HJ. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res 2009; 171:155-63.
34. Lee RK. Epidemic tinea capitis; a public health problem. Yale J Biol Med 1947; 19:547-55.
35. Shore RE, Albert RE, Pasternack BS. Follow-up study of patients treated by X-ray epilation for Tinea capitis; resurvey of posttreatment illness and mortality experience. Arch Environ Health 1976; 31:21-8.
36. Cipollaro AC, Kallos A, Ruppe JP, Jr. Measurement of gonadal radiations during treatment for tinea capitis. N Y State J Med 1959; 59:3033-40.
37. Albert RE, Omran AR, Brauer EW, Cohen NC, Schmidt H, Dove DC, et al. Follow-up study of patients treated by x-ray epilation for tinea capitis. II. Results of clinical and laboratory examinations. Arch Environ Health 1968; 17:919-34.
38. Ben Hamla A, Joucdar S. [Malignant degeneration of radiodermatitis of the scalp after radiotherapy for tinea. Apropos of 10 lesions]. Ann Chir Plast Esthet 1985; 30:335-7. (article in French)
39. Pousti A. Malignant tumours of the scalp resulting from X-ray treatment of tinea capitis. Br J Plast Surg 1979; 32:52-4.
40. Ridley CM. Basal cell carcinoma following x-ray epilation of the scalp. Br J Dermatol 1962; 74:222-3.
41. Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with x rays. Br Med J (Clin Res Ed) 1982; 284(6314):449-60.
42. Shore RE, Moseson M, Xue X, Tse Y, Harley N, Pasternack BS. Skin cancer after X-ray treatment for scalp ringworm. Radiat Res 2002; 157:410-8.
43. Karagas MR, McDonald JA, Greenberg ER, Stukel TA, Weiss JE, Baron JA, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst 1996; 88:1848-53.
44. Zargari O. Radiation-induced basal cell carcinoma. Dermatol Pract Concept 2015; 5:109-12.
45. Mseddi M, Bouassida S, Marrekchi S, Khemakhem M, Gargouri N, Turki H, et al. [Basal cell carcinoma of the scalp after radiation therapy for tinea capitis: 33 patients]. Cancer Radiother 2004; 8:270-3. (article in French)
46. Hassanpour SE, Kalantar-Hormozi A, Motamed S, Moosavizadeh SM, Shahverdiani R. Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients. Ann Plast Surg 2006; 57:509-12.
47. Boaventura P, Pereira D, Mendes A, Batista R, da Silva AF, Guimaraes I, et al. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. J Dermatol Sci 2014; 73:31-9.
48. Tessone A, Amariglio N, Weissman O, Jacob-Hirsch J, Liran A, Stavrou D, et al. Radiotherapy-induced basal cell carcinomas of the scalp: are they genetically different? Aesthetic Plast Surg 2012; 36:1387-92.
49. Russo GL, Picano E. The effects of radiation exposure on interventional cardiologists. Eur Heart J 2012; 33:423-4.
50. Eagan JT, Jr., Jones CT. Cutaneous cancers in an interventional cardiologist: a cautionary tale. J Interv Cardiol 2011; 24:49-55.
51. Kim KP, Miller DL, Berrington de Gonzalez A, Balter S, Kleinerman RA, Ostroumova E, et al. Occupational radiation doses to operators performing fluoroscopically-guided procedures. Health Phys 2012; 103:80-99.
52. Picano E, Vano E. The radiation issue in cardiology: the time for action is now. Cardiovasc Ultrasound 2011; 9:35.
53. Wang JX, Inskip PD, Boice JD, Jr., Li BX, Zhang JY, Fraumeni JF, Jr. Cancer incidence among medical diagnostic X-ray workers in China, 1950 to 1985. Int J Cancer 1990; 45:889-95.
54. Wang JX, Zhang LA, Li BX, Zhao YC, Wang ZQ, Zhang JY, et al. Cancer incidence and risk estimation among medical x-ray workers in China, 1950-1995. Health Phys 2002; 82:455-66.
55. Lee T, Sigurdson AJ, Preston DL, Cahoon EK, Freedman DM, Simon SL, et al. Occupational ionising radiation and risk of basal cell carcinoma in US radiologic technologists (1983-2005). Occup Environ Med 2015.
56. Dauer LT, Brooks AL, Hoel DG, Morgan WF, Stram D, Tran P. Review and evaluation of updated research on the health effects associated with low-dose ionising radiation. Radiat Prot Dosimetry 2010; 140:103-36.
57. Zakeri F, Hirobe T, Akbari Noghabi K. Biological effects of lowdose ionizing radiation exposure on interventional cardiologists. Occup Med (Lond) 2010; 60:464-9.
58. Borghini A, Mercuri A, Turchi S, Chiesa MR, Piccaluga E, Andreassi MG. Increased circulating cell-free DNA levels and mtDNA fragments in interventional cardiologists occupationally exposed to low levels of ionizing radiation. Environ Mol Mutagen 2015; 56:293-300.
59. Andreassi MG, Cioppa A, Botto N, Joksic G, Manfredi S, Federici C, et al. Somatic DNA damage in interventional cardiologists: a case-control study. FASEB J 2005; 19:998-9.
60. Alves JG, Mairos JC. In-flight dose estimates for aircraft crew and pregnant female crew members in military transport missions. Radiat Prot Dosimetry 2007; 125(1-4):433-7.
61. Zeeb H, Hammer GP, Blettner M. Epidemiological investigations of aircrew: an occupational group with low-level cosmic radiation exposure. J Radiol Prot 2012; 32:N15-9.
62. Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, et al. The risk of melanoma in airline pilots and cabin crew: a meta-analysis. JAMA Dermatol 2015; 151:51-8.
63. Zeeb H, Blettner M, Langner I, Hammer GP, Ballard TJ, Santaquilani M, et al. Mortality from cancer and other causes among airline cabin attendants in Europe: a collaborative cohort study in eight countries. Am J Epidemiol 2003; 158:35-46.
64. Yong LC, Sigurdson AJ, Ward EM, Waters MA, Whelan EA, Petersen MR, et al. Increased frequency of chromosome translocations in airline pilots with long-term flying experience. Occup Environ Med 2009; 66:56-62.
65. Bolzan AD, Bianchi MS, Gimenez EM, Flaque MC, Ciancio VR. Analysis of spontaneous and bleomycin-induced chromosome damage in peripheral lymphocytes of long-haul aircrew members from Argentina. Mutat Res 2008; 639(1-2):64-79.
66. Wolf G, Obe G, Bergau L. Cytogenetic investigations in flight personnel. Radiat Prot Dosimetry 1999; 86:275-8.
67. Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S. The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes. JAMA Dermatol 2015; 151:450-2.
68. Lubin JH, Boice JD, Jr., Edling C, Hornung RW, Howe G, Kunz E, et al. Radon-exposed underground miners and inverse doserate (protraction enhancement) effects. Health Phys 1995; 69:494-500.
69. Veiga LH, Melo V, Koifman S, Amaral EC. High radon exposure in a Brazilian underground coal mine. J Radiol Prot 2004; 24:295-305.
70. Keil AP, Richardson DB, Troester MA. Healthy worker survivor bias in the Colorado Plateau uranium miners cohort. Am J Epidemiol 2015; 181:762-70.
71. Robertson A, Allen J, Laney R, Curnow A. The cellular and molecular carcinogenic effects of radon exposure: a review. Int J Mol Sci 2013; 14:14024-63.
72. Tirmarche M, Harrison JD, Laurier D, Paquet F, Blanchardon E, Marsh JW, et al. ICRP Publication 115. Lung cancer risk from radon and progeny and statement on radon. Ann ICRP 2010; 40:1-64.
73. Charles MW. Radon exposure of the skin: I. Biological effects. J Radiol Prot 2007; 27:231-52.
74. Kendall GM, Smith TJ. Doses to organs and tissues from radon and its decay products. J Radiol Prot 2002; 22:389-406.
75. Eatough JP, Henshaw DL. Radon and thoron associated dose to the basal layer of the skin. Phys Med Biol 1992; 37:955-67.
76. Eatough JP. Alpha-particle dosimetry for the basal layer of the skin and the radon progeny 218-Po and 214-Po. Phys Med Biol 1997; 42:1899-911.
77. Charles MW. Radon exposure of the skin: II. Estimation of the attributable risk for skin cancer incidence. J Radiol Prot 2007; 27:253-74.
78. Sevcova M, Sevc J, Thomas J. Alpha irradiation of the skin and the possibility of late effects. Health Phys 1978; 35:803-6.
79. Sevcova M, Horacek J, Sevc J. [Occupational basalioma in external alpha radiation hazards (author's transl)]. Cas Lek Cesk 1978; 117:1442-4. (article in Czech)
80. Brauner EV, Loft S, Sorensen M, Jensen A, Andersen CE, Ulbak K, et al. Residential radon exposure and skin cancer incidence in a prospective Danish cohort. PLoS One 2015; 10:e0135642.
81. Wheeler BW, Kothencz G, Pollard AS. Geography of nonmelanoma skin cancer and ecological associations with environmental risk factors in England. Br J Cancer 2013; 109:235-41.
82. Muirhead CR, Kendall GM, Darby SC, Doll R, Haylock RG, O'Hagan JA, et al. Epidemiological studies of UK test veterans: II. Mortality and cancer incidence. J Radiol Prot 2004; 24:219-41.
83. Muirhead CR, Bingham D, Haylock RG, O'Hagan JA, Goodill AA, Berridge GL, et al. Follow up of mortality and incidence of cancer 1952-98 in men from the UK who participated in the UK's atmospheric nuclear weapon tests and experimental programmes. Occup Environ Med 2003; 60:165-72.
84. Thaul SFPW, Harriet C, Maonaigh HO. The five series study: mortality of military participants in U.S. nuclear weapons tests (2000): The National Academies Press; 2000.
85. Morrissey WM, Jr., Murphy RX, Jr., Scarlato M. Nonmelanomatous skin cancer following exposure to atomic radiation in the United States. Plast Reconstr Surg 1998; 101:431-3.
86. Nelson KL, Randle HW. Skin cancer in an atomic veteran: cause or coincidence? Dermatol Surg 2003; 29:1100-4.
87. Berking C, Hauschild A, Kolbl O, Mast G, Gutzmer R. Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int 2014; 111:389-95.
88. Cho M, Gordon L, Rembielak A, Woo TC. Utility of radiotherapy for treatment of basal cell carcinoma: a review. Br J Dermatol 2014; 171:968-73.
89. Caccialanza M, Percivalle S, Piccinno R. Possibility of treating basal cell carcinomas of nevoid basal cell carcinoma syndrome with superficial x-ray therapy. Dermatology 2004; 208:60-3.
90. Pollom EL, Bui TT, Chang AL, Colevas AD, Hara WY. Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma. JAMA Dermatol 2015.
91. Wilder RB, Shimm DS, Kittelson JM, Rogoff EE, Cassady JR. Recurrent basal cell carcinoma treated with radiation therapy. Arch Dermatol 1991; 127:1668-72.
92. Caccialanza M, Piccinno R, Cuka E, Alberti Violetti S, Rozza M. Radiotherapy of morphea-type basal cell carcinoma: results in 127 cases. J Eur Acad Dermatol Venereol 2014; 28:1751-5.
93. Smith SP, Grande DJ. Basal cell carcinoma recurring after radiotherapy: a unique, difficult treatment subclass of recurrent basal cell carcinoma. J Dermatol Surg Oncol 1991; 17:26-30.
94. Poplack PA, Pizzo DG. Principles and practice of pediatric oncology. 3rd ed: Lippincott-raven; 1997.
95. Liu Y, Zhu Y, Gao L, Xu G, Yi J, Liu X, et al. Radiation treatment for medulloblastoma: a review of 64 cases at a single institute. Jpn J Clin Oncol 2005; 35:111-5.
96. O'Malley S, Weitman D, Olding M, Sekhar L. Multiple neoplasms following craniospinal irradiation for medulloblastoma in a patient with nevoid basal cell carcinoma syndrome. Case report. J Neurosurg 1997; 86:286-8.
97. Marin-Gutzke M, Sanchez-Olaso A, Berenguer B, Gonzalez B, Rodriguez P, De Salamanca JE, et al. Basal cell carcinoma in childhood after radiation therapy: case report and review. Ann Plast Surg 2004; 53:593-5.
98. Walter AW, Pivnick EK, Bale AE, Kun LE. Complications of the nevoid basal cell carcinoma syndrome: a case report. J Pediatr Hematol Oncol 1997; 19:258-62.
99. Mancuso M, Pazzaglia S, Tanori M, Hahn H, Merola P, Rebessi S, et al. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice. Cancer Res 2004; 64:934-41.
100. Campbell RM, Mader RD, Dufresne RG, Jr. Meningiomas after medulloblastoma irradiation treatment in a patient with basal cell nevus syndrome. J Am Acad Dermatol 2005; 53(5 Suppl 1): S256-9.
101. Wallin JL, Tanna N, Misra S, Puri PK, Sadeghi N. Sinonasal carcinoma after irradiation for medulloblastoma in nevoid basal cell carcinoma syndrome. Am J Otolaryngol 2007; 28:360-2.
102. Golitz LE, Norris DA, Luekens CA, Jr., Charles DM. Nevoid basal cell carcinoma syndrome. Multiple basal cell carcinomas of the palms after radiation therapy. Arch Dermatol 1980; 116:1159-63.
103. Evans DG, Birch JM, Orton CI. Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome. Br J Neurosurg 1991; 5:643-6.
104. Howell JB. Nevoid basal cell carcinoma syndrome. Profile of genetic and environmental factors in oncogenesis. J Am Acad Dermatol 1984; 11:98-104.
105. Telfer NR, Colver GB, Morton CA, British Association of D. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159:35-48.
106. Widel M, Przybyszewski W, Rzeszowska-Wolny J. [Radiationinduced bystander effect: the important part of ionizing radiation response. Potential clinical implications]. Postepy Hig Med Dosw (Online) 2009; 63:377-88. (article in Polish)
107. Biedermann KA, Sun JR, Giaccia AJ, Tosto LM, Brown JM. scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. Proc Natl Acad Sci U S A 1991; 88:1394-7.
108. Mancuso M, Leonardi S, Giardullo P, Pasquali E, Tanori M, De Stefano I, et al. Oncogenic radiation abscopal effects in vivo: interrogating mouse skin. Int J Radiat Oncol Biol Phys 2013; 86:993-9.
109. Chen YJ, Lin CP, Hsu ML, Shieh HR, Chao NK, Chao KS. Sonic hedgehog signaling protects human hepatocellular carcinoma cells against ionizing radiation in an autocrine manner. Int J Radiat Oncol Biol Phys 2011; 80:851-9.
110. Leonard JM, Ye H, Wetmore C, Karnitz LM. Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability. J Cell Biol 2008; 183:385-91.
111. Tsai CL, Hsu FM, Tzen KY, Liu WL, Cheng AL, Cheng JC. Sonic hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma. J Gastroenterol Hepatol 2015; 8:1317-24.
112. Zeng J, Aziz K, Chettiar ST, Aftab BT, Armour M, Gajula R, et al. Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. Int J Radiat Oncol Biol Phys 2013; 86:143-9.
113. Tripathi K, Mani C, Barnett R, Nalluri S, Bachaboina L, Rocconi RP, et al. Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors. J Biol Chem 2014; 289:31513-25.
114. Harrison W, Cochrane B, Neill G, Philpott M. The oncogenic GLI transcription factors facilitate keratinocyte survival and transformation upon exposure to genotoxic agents. Oncogene 2014; 33:2432-40.
115. Mille F, Tamayo-Orrego L, Levesque M, Remke M, Korshunov A, Cardin J, et al. The Shh receptor Boc promotes progression of early medulloblastoma to advanced tumors. Dev Cell 2014; 31:34-47.
116. Chung JH, Larsen AR, Chen E, Bunz F. A PTCH1 homolog transcriptionally activated by p53 suppresses Hedgehog signaling. J Biol Chem 2014; 289:33020-31.
117. Abe Y, Oda-Sato E, Tobiume K, Kawauchi K, Taya Y, Okamoto K, et al. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc Natl Acad Sci U S A 2008; 105:4838-43.
118. Li ZJ, Mack SC, Mak TH, Angers S, Taylor MD, Hui CC. Evasion of p53 and G2/M checkpoints are characteristic of Hhdriven basal cell carcinoma. Oncogene 2014; 33:2674-80.
119. Zhang H, Ping XL, Lee PK, Wu XL, Yao YJ, Zhang MJ, et al. Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am J Pathol 2001; 158:381-5.
120. Tanori M, Mancuso M, Pasquali E, Leonardi S, Rebessi S, Di Majo V, et al. PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma. Carcinogenesis 2008; 29:1911-9.
121. Mancuso M, Gallo D, Leonardi S, Pierdomenico M, Pasquali E, De Stefano I, et al. Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis 2009; 30:340-7.
122. Brennan-Crispi DM, Hossain C, Sahu J, Brady M, Riobo NA, Mahoney MG. Crosstalk between Desmoglein 2 and Patched 1 accelerates chemical-induced skin tumorigenesis. Oncotarget 2015; 6:8593-605.
123. Mancuso M, Leonardi S, Tanori M, Pasquali E, Pierdomenico M, Rebessi S, et al. Hair cycle-dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+ mice exposed to radiation. Cancer Res 2006; 66:6606-14.
124. Tauber G, Pavlovsky L, Fenig E, Hodak E. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp. J Am Acad Dermatol 2015.
125. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326:572-4.
126. Aasi S, Silkiss R, Tang JY, Wysong A, Liu A, Epstein E, et al. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol 2013; 149:242-3.
127. Gill HS, Moscato EE, Chang AL, Soon S, Silkiss RZ. Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol 2013; 131:1591-4.
128. Hedgehog Pathway Inhibitor Approved for Skin Cancer. Cancer Discov 2015. (Published Online August 19, 2015; doi: 10.1158/2159-8290.CD-NB2015-121)
129. Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014; 32:745-51.
130. Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013; 23:23-34.